-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
UK Home Asking Prices Drop £6,745 in November Amid High Mortgage Rates
-
Mbeki Claims No Progress Since 2018; Author Cites Infrastructure and Economic Gains
-
Alex Georgiev Sets Personal Record to Win NCAA Pole Vault at Penn Relays
-
Qatar's Amir and Venezuelan Acting President Discuss Energy Cooperation
-
NuRAN Wireless Eliminates Floating-Price Preferred Overhang and Locks In a Fixed C$1.20 Conversion Price
-
SMX: The Future of Gold Will Be Defined by What We Know About It -Powering Verified Trade and Tokenisation
-
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
-
Cardiff Lexington Announces Third Quarter 2026 Financial Results
-
Expecting a Refund but Owe Back Taxes? Clear Start Tax Explains How the IRS Offset Program Takes It First
-
MicroVision Lidar Powers Commercial Driverless Trucking at Scale with Kodiak AI
-
Rescue Intellitech Expands Professional Decontamination Portfolio for Fire Departments with DeconWasher(TM) Pro S
-
Westell Technologies, Inc. Announces Its Commencing a Tender Offer
-
SMX Brings a New Level of Transparency to Gold Trading Through trueGold Technology
-
Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
-
Wi2Wi Reports 35% Revenue Growth to US$2.36M and Returns to Profitability with US$268K Net Income in Q3 2026
-
Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia
-
Gladstone Capital Corporation Earnings Call and Webcast Information
-
Medical Care Technologies Inc. (OTCID:MDCE) Follows Q3 Profit Surge With Confirmed Software Development and Expanding Subsidiary Activity
-
GameSquare Holdings Reports 2026 Third Quarter Results with Revenue up 77% YoY and Net Income Reaches $10.1 Million
-
ValorPay UAB Goes Live on T2, the Eurosystem's Real-Time Settlement System
-
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
-
XCF Global Reports Third Quarter 2026 Financial Results & Affirms 2027 Outlook
-
NextSource Materials Appoints Eugene Lee as Chief Financial Officer
-
International Battery Metals Ltd. Reports Second Quarter of Fiscal Year 2027 Financial Results
-
Abasca Resources Engages Northern Arc Public Affairs to Advance Federal Engagement on the Loki Flake Graphite Project
-
AsiaFIN Holdings Corp. Announces Third Quarter 2026 Results, Reporting Strong Nine-Month Financial Performance with Improved Margins
-
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
-
Strategic Metals Reports Promising Results From the Rusty and Ranch Projects
-
Golden Minerals Reports Third Quarter 2026 Financial Results
Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials
VANCOUVER, BC / ACCESS Newswire / July 4, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into an agreement with Nucro-Technics Inc. ("Nucro-Technics"), dated July 3, 2025, pursuant to which Nucro-Technics is to conduct a broad range of preclinical studies in support of the Company's lead drug candidate. These specialized lab tests are intended to characterize the drug's behavior in animal and in vitro models, including its bioavailability, biodistribution, pharmacokinetics profile, as well as to assess its safety through regulatory compliant toxicology testing. Together, these studies represent a major step forward in Onco's path toward human clinical trials, enabling key safety evaluations and supporting a series of required animal studies. The work program includes two main components: drug metabolism testing (in vitro ADME studies) and formal safety studies conducted under Good Laboratory Practice (GLP) standards, as required by regulators before first-in-human use. This work will support the development of Onco's exclusively licensed Polynucleotide Kinase Phosphatase (PNKP) inhibitor (the "Technology").
Nucro-Technics is a Toronto-based, Health Canada- and FDA-inspected contract research organization with 55 years of experience supporting GLP and GMP testing for a variety of therapeutic indications. Now part of Frontage Laboratories, Nucro-Technics specializes in GLP-compliant toxicology, pharmacokinetics, in vitro ADME, and analytical services for biotechnology and pharmaceutical clients.
The contract with Nucro-Technics covers the full scope of IND-enabling work for Onco's lead program, NP/A83 (OI-83463), a polymer-encapsulated PNKP inhibitor being developed for patients with advanced-stage, PTEN- or SHP-1-deficient cancers. In addition to drug behaviour and safety testing, the agreement provides for key supporting activities such as validating the analytical methods used to measure the drug in biological samples, evaluating the safety of the novel polymer delivery system (mPEO-bPBCL), and assembling submission-ready data packages for regulatory review. This integrated preclinical program is designed to meet both FDA and Health Canada standards and to generate the data required for an Investigational New Drug (IND) application and the initiation of Phase I/II clinical trials.
This agreement marks a significant step in Onco's regulatory preparation efforts, as the studies conducted are aimed at generating both pharmacokinetic and safety data essential for moving the Technology into clinical testing. The ADME results are intended to reveal key insights into the drug's stability and metabolism in the body, while the GLP-compliant toxicology studies are intended to evaluate the safety of both the compound and its novel delivery system. Together, these data are expected to form the foundation of the Company's IND submission and support the design of its first-in-human clinical trials.
"Our PNKP inhibitor represents a novel approach to targeting DNA repair vulnerabilities in cancer, and a deep understanding of both its behaviour in the body and its safety profile is crucial to unlocking its full therapeutic potential. The studies we have contracted Nucro-Technics to conduct are intended to not only support our IND filing but to also help guide formulation and dosing strategies as we move towards clinical development. This is more than a regulatory compliance exercise; it's an opportunity to build a robust foundation for long-term success," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the benefits expected to be realized under the agreement with Nucro-Technics, and the Company's ability to move forward with its plans for regulatory approvals and the conduct of human and other further testing of its Technologies, the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
Th.Gonzalez--AT